Calf Lung Surfactant Recovers Surface Functionality after Exposure to Aerosols Containing Polymeric Particles

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 29, Issue 1, 2016, Pages 10-23

  Farnoud, Amir M ^a   Fiegel, Jennifer ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Aerosol; Infasurf; nanoparticles; surface tension; surfactant inhibition

Indexed keywords

CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; POLYSTYRENE;

AEROSOL; ARTICLE; CHEMICAL COMPOSITION; COMPRESSION; CONTROLLED STUDY; ISOTHERM; LIGHT ABSORPTION; PARTICLE SIZE; PRESSURE; SURFACE AREA; SURFACE PROPERTY; SURFACE TENSION; TENSIOMETRY; ZETA POTENTIAL;

EID: 84941227837     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2014.1165     Document Type: Article

References (56)

1. Frerking I, Gunther A, Seeger W, and Pison U: Pulmonary surfactant: Functions, abnormalities and therapeutic options. J Intensive Care Med. 2001;27:1699-1717.
2. Al-Hallak MHDK, Azarmi S, Sun C, Lai P, Prenner EJ, Roa W, and Lobenberg R: Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles in vitro and in vivo evaluation. AAPS J. 2010;12:294-299.
3. Bakshi MS, Zhao L, Smith R, Possmayer F, and Petersen NO: Metal nanoparticle pollutants interfere with pulmonary surfactant function in vitro. Biophy J. 2008;94:855-868.
4. Guzman E, Liggieri L, Santini E, Ferrari M, and Ravera F: DPPC-DOPC Langmuir monolayers modified by hydrophilic silica nanoparticles: Phase behaviour, structure and rheology. Colloids Surf A, Physicochem Eng Asp. 2011: 174-183.
5. Guzman E, Liggieri L, Santini E, Ferrari M, and Ravera F: Effect of hydrophilic and hydrophobic nanoparticles on the surface pressure response of DPPC monolayers. J Phys Chem C, Nanomater Interfaces. 2011;115:21715-21722.
6. Guzman E, Liggieri L, Santini E, Ferrari M, and Ravera F: Mixed DPPC-cholesterol Langmuir monolayers in presence of hydrophilic silica nanoparticles. Colloids Surf B, Biointerfaces. 2013;105:284-293.
7. Schleh C, Muhlfeld C, Pulskamp K, Schmiedl A, Nassimi M, Lauenstein HD, Braun A, Krug N, Erpenbeck VJ, and Hohlfeld JM: The effect of titanium dioxide nanoparticles on pulmonary surfactant function and ultrastructure. Respir Res. 2009;10:90-101.
8. Beck Broichsitter M, Ruppert C, Schmehl T, Guenther A, Betz T, Bakowsky U, Seeger W, Kissel T, and Gessler T: Biophysical investigation of pulmonary surfactant surface properties upon contact with polymeric nanoparticles in vitro. Nanomedicine. 2010;7:341-350.
9. Dwivedi MV, Harishchandra RK, Koshkina O, Maskos M, and Galla HJ: Size influences the effect of hydrophobic nanoparticles on lung surfactant model systems. Biophys J. 2014;106:289-298.
10. Fan Q, Wang YE, Zhao X, Loo JSC, and Zuo YY: Adverse biophysical effects of hydroxyapatite nanoparticles on natural pulmonary surfactant. ACS Nano. 2011;5: 6410-6416.
11. Farnoud AM, and Fiegel J: Low concentrations of negatively charged sub-micron particles alter the microstructure of DPPC at the air-water interface. Colloids Surf A, Physicochem Eng Asp. 2012;415:320-327.
12. Farnoud AM, and Fiegel J: Interaction of dipalmitoyl phosphatidylcholine monolayers with a particle-laden subphase. J Phys Chem B. 2013;117:12124-12134.
13. Valle RP, Huang CL, Loo SCJ, and Zuo YY: Increasing hydrophobicity of nanoparticles intensifies lung surfactant film inhibition and particle retention. ACS Sustainable Chem Eng. 2014;2:1574-1580.
14. Im Hof V, Gehr P, Gerber V, Lee M, and Schurch S: In vivo determination of surface tension in the horse trachea and in vitro model studies. Respir Physiol Neurobiol. 1997;109: 81-93.
15. Duncan SL, and Larson RG: Comparing experimental and simulated pressure-area isotherms for DPPC. Biophys J. 2008;94:2965-2986.
16. Harishchandra RK, Saleem M, and Galla HJ: Nanoparticle interaction with model lung surfactant monolayers. J R Soc Interface. 2010;7:15-26.
17. Kanishtha T, Banerjee R, and Venkataraman C: Effect of particle emissions from biofuel combustion on surface activity of model and therapeutic pulmonary surfactants. Environ Toxicol Pharmacol. 2006;22:325-333.
18. Lai P, Nathoo S, Ku T, Gill S, Azarmi S, Roa W, Lobenberg R, and Prenner EJ: Real-time imaging of interactions between dipalmitoylphosphatidylcholine monolayers and gelatin based nanoparticles using Brewster angle microscopy. J Biomed Nanotechnol. 2010;6:145-152.
19. Sosnowski TR, Gradon L, and Podgorski A: Influence of insoluble aerosol deposits on the surface activity of the pulmonary surfactant: A possible mechanism of alveolar clearance retardation? Aerosol Sci Tech. 2000;32:52-60.
20. Stuart D, Lobenberg R, Ku T, Azarmi S, Ely L, Roa W, and Prenner EJ: Biophysical investigation of nanoparticle interactions with lung surfactant model systems. J Biomed Nanotechnol. 2006;2:245-252.
21. Beck-Broichsitter M, Ruppert C, Schmehl T, Gunther A, and Seeger W: Biophysical inhibition of synthetic vs. naturally-derived pulmonary surfactant preparations by polymeric nanoparticles. Biochim Biophys Acta. 2014;1838: 474-481.
22. Doshi N, and Mitragotri S: Macrophages recognize size and shape of their targets. PLoS One. 2010;5:e10051.
23. Champion JA, Walker A, and Mitragotri S: Role of particle size in phagocytosis of polymeric microspheres. Pharmaceut Res. 2008;25:1815-1821.
24. Abramoff MD, Magalhaes PJ, and Ram SJ: Image processing with ImageJ. Biophotonics Intl. 2004;11:36-42.
25. Hardy NJ, Richardson TH, and Grunfeld F: Minimising monolayer collapse on Langmuir troughs. Colloids Surf A Physicochem Eng Asp. 2006;284-285:202-206.
26. Bachofen H, Schurch S, Urbinelli M, and Weibel E: Relations among alveolar surface tension, surface area, volume, and recoil pressure. J Appl Physiol. 1987;62:1878-1887.
27. Horie T, Ardila R, and Hildebrandt J: Static and dynamic properties of excised cat lung in relation to temperature. J Appl Physiol. 1974;36:317-322.
28. Schurch S, Bachofen H, and Weibel ER: Alveolar surface tensions in excised rabbit lungs: Effect of temperature. Respir Physiol Neurobiol. 1985;62:31-45.
29. Smith JC, and Stamenovic D: Surface forces in lungs. I. Alveolar surface tension-lung volume relationships. J Appl Physiol. 1986;60:1341-1350.
30. Levitzky MG: Pulmonary Physiology: Lange Physiology Series. McGraw-Hill: New York City, NY: 1995; p. 57.
31. Irache J, Durrer C, Ponchel G, and Duchene D: Determination of particle concentration in latexes by turbidimetry. Int J Pharm. 1993;90:9-12.
32. Farnoud AM: Interaction of polymeric particles with surfactant interfaces. PhD Thesis. The University of Iowa, 2013.
33. Lee KYC: Collapse mechanisms of Langmuir monolayers. Annu Rev Phys Chem. 2008;59:771-791.
34. Wustneck R: Interfacial properties of pulmonary surfactant layers. Adv Colloid Interface Sci. 2005;117:33-58.
35. Bloom BT, Kattwinkel J, Hall RT, Delmore PM, Egan EA, Trout JR, Malloy MH, Brown DR, Holzman IR, and Coghill CH: Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics. 1997;100:31-38.
36. Wang YE, Zhang H, Fan Q, Neal CR, and Zuo YY: Biophysical interaction between corticosteroids and natural surfactant preparation: Implications for pulmonary drug delivery using surfactant as a carrier. Soft Matter. 2012; 8:504-511.
37. Zhang H, Fan Q, Wang YE, Neal CR, and Zuo YY: Comparative study of clinical pulmonary surfactants using atomic force microscopy. Biochim Biophys Acta. 2011;1808:1832-1842.
38. Zhang H,Wang YE, Fan Q, and Zuo YY: On the low surface tension of lung surfactant. Langmuir. 2011;27:8351-8358.
39. Kendall M, and Holgate S: Health impact and toxicological effects of nanomaterials in the lung. Respirology.17:743-758.
40. Avery ME, and Mead J: Surface properties in relation to atelectasis and hyaline membrane disease. Arch Pediatr Adolesc Med. 1959;97:517-523.
41. Holm BA, Notter R, and Finkelstein JN: Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem Phys Lipids. 1985;38:287-298.
42. Ku T, Gill S, Lobenberg R, Azarmi S, Roa W, and Prenner EJ: Size dependent interactions of nanoparticles with lung surfactant model systems and the significant impact on surface potential. J Nanosci Nanotechnol. 2008;8:2971-2978.
43. Trivedi R, Redente EF, Thakur A, Riches DW, and Kompella UB: Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology. 2012;23:505101.
44. Berg JC: Introduction to Interfaces and Colloids. World Scientific: Hackensack, NJ; 2009; pp. 547-550.
45. Lippmann M: Regional deposition of particles in the human respiratory tract. In: DHK Lee, HL Falk, SD Murphy, (eds). Handbook of Physiology, Section 9: Reactions to Environmental Agents Handbook of Physiology, Section 9: Reactions to Environmental Agents, American Physiology Society, Bethesda, MD; 1977; pp. 213-232.
46. Kendall M: Fine airborne urban particles (PM 2.5) sequester lung surfactant and amino acids from human lung lavage. Am J Physiol Lung Cell Mol Physiol. 2007;293: 1053-1058.
47. Wang Z, Li X, and Yang S: Studies of dipalmitoylphosphatidylcholine (DPPC) monolayers embedded with endohedral metallofullerene (Dy@ C82). Langmuir. 2009;25: 12968-12973.
48. Wiecek A, Dyranowicz-Latka P, Vila-Romeu N, Nieto-Suarez M, and Flasinski M: Interactions between an anticancer drugedelfosineand DPPC in Langmuir monolayers. Colloids Surf A, Physicochem Eng Asp. 2008;321:201-205.
49. Schurch S, Gehr P, Im Hof V, Geiser M, and Green F: Surfactant displaces particles toward the epithelium in airways and alveoli. Respir Physiol Neurobiol. 1990;80:17-32.
50. Gehr P, Geiser M, Im Hof V, Schurch S, Waber U, and Baumann M: Surfactant and inhaled particles in the conducting airways: Structural, stereological, and biophysical aspects. Microsc Res Tech. 1993;26:423-436.
51. Perez Gil J: Interfacial properties of surfactant proteins. Biochim Biophys Acta. 1998;1408:203.
52. Baritussio AG, Magoon MW, Goerke J, and Clements JA: Precursor-product relationship between rabbit type II cell lamellar bodies and alveolar surface-active material: surfactant turnover time. Biochim Biophys Acta. 1981;666: 382-393.
53. Hildebran JN, Goerke J, and Clements JA: Pulmonary surface film stability and composition. J Appl Physiol Respir Environ Exerc Physiol. 1979;47:604-611.
54. Possmayer F, Nag K, Rodriguez K, Qanbar R, and Schurch S: Surface activity in vitro: Role of surfactant proteins. Comp Biochem Physiol A Mol Integr Physiol. 2001;129: 209-220.
55. Tatur S, and Badia A: Influence of hydrophobic alkylated gold nanoparticles on the phase behavior of monolayers of DPPC and clinical lung surfactant. Langmuir. 2012;28: 628-639.
56. Geiser M, Schurch S, and Gehr P: Influence of surface chemistry and topography of particles on their immersion into the lung's surface-lining layer. J Appl Physiol. 2003;94: 1793-1801.